The scientific founders and advisors of Evox are world-leading exosome scientists and physicians, with expertise in all aspects from exosome biology and purification to targeted drug delivery systems and treatment of rare life-threatening diseases.
Dr Antonin de Fougerolles
Chief Executive Officer
Tony has over 20 years’ experience in the pharmaceutical and biotechnology industry. He has a strong background in successfully developing and advancing multiple different transformative therapeutic drug platforms in both the nucleic acid and biologics space. In addition, his in-depth expertise in drug development has led to the progression of multiple assets through clinical trials, as well as playing a key role in the negotiation of major partnerships. Prior to joining Evox Therapeutics, Tony was CSO at Ablynx NV and Moderna Therapeutics, and VP Research at Alnylam Pharmaceuticals. PhD in Immunology from Harvard University.
Dr Per Lundin
Co-Founder and Chief Operating Officer
European Patent Attorney with considerable business development and IP strategy experience. Previously at Thomson Reuters IP & Science; founder and CEO of IsletOne Therapeutics, a cell therapy company spun out from the Karolinska Institute; Patent Attorney in private practice. Per started his career as Scientist within nanoparticle drug delivery with Australian biotech company Apollo Life Sciences. PhD from the Karolinska Institute, MBA from Stockholm University.
Dr David Virley
Head of Research
David has over 20 years experience in the bio-pharmaceutical and R&D industry. He has expertise in advancing neuroscience-based programs to the clinic, for a range of CNS disorders. In addition, his in-depth expertise in drug development has led to the progression of multiple assets through clinical trials, as well as playing a key role in the negotiation of major partnerships. Prior to joining Evox Therapeutics, David was Head of Pharmacology at AbbVie in Germany, and also worked at GlaxoSmithKline (GSK) for 10 years. David is a Pharmacologist/Neuroscientist by training, obtaining his Ph.D. from the Institute of Psychiatry at King’s College London.